Dec 22, 2019
President Donald Trump's Environmental Protection Agency--already accused of being "pesticide cheerleader"--threw its weight behind chemical company Bayer AG on Friday when the agency asked a federal appeals court to reverse a lower court's ruling in favor of a man who said the company's Roundup weedkiller was responsible for his cancer.
The case centers on Edwin Hardeman of California, who was diagnosed with non-Hodgkin's lymphoma in 2015 after using the glyphosate-based pesticide, made by Monsanto, for years on his property. Bayer acquired Monsanto last year.
The EPA maintains--to the outrage of environmental and public health groups--that glyphosate is not a carcinogen. The federal decision notwithstanding, California in 2017 agreed with the World Health Organization's 2015 classification of glyphosate as a "probable carcinogen." Trump's EPA has pushed back on the state's finding and said that product labels informing users of that cancer risk would "misbranding" and announced in August of this year that the agency would not approve of labels carrying that warning.
In an amicus brief filed Friday with the U.S. Court of Appeals for the Ninth Circuit, attorneys with the EPA and Justice Department said,
EPA approved the label for the pesticide/herbicide at issue here, Roundup, through a registration process that did not require a cancer warning. In fact, EPA has never required a labeling warning of a cancer risk posed by Roundup, and such a warning would be inconsistent with the agency's scientific assessments of the carcinogenic potential of the product. Mr. Hardeman nevertheless sought damages under California common law, alleging that Monsanto had failed to adequately warn consumers of cancer risks posed by the active ingredient in Roundup. FIFRA therefore preempts Mr. Hardeman's claims to the extent that they are based on the lack of a warning on Roundup's labeling.
The filing from the federal government came the same week Bayer AG asked the appeals court to toss out the lower court's ruling and defended Roundup's safety.
Bayer is currently facing nearly 43,000 claims related to glyphosate-linked cancer in federal courts. An end to the company's legal woes is unlikely to happen soon, according toBloomberg Environment.
"The only vehicle that remotely approaches [an end to litigation] might be bankruptcy," Loyola Law School professor Adam Zimmerman told the outlet last week. "Short of that, or some victories in court, I don't see what kind of arrangement would absolve them of future liability."
We're optimists who believe in the power of informed and engaged citizens to ignite and enact change to make the world a better place.
We're hundreds of thousands strong, but every single supporter counts.
Your contribution supports this new media model—free, independent, and dedicated to uncovering the truth. Stand with us in the fight for social justice, human rights, and equality. As a people-powered nonprofit news outlet, we cover the issues the corporate media never will. Join with us today!
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.